4:44 PM
 | 
May 23, 2019
 |  BC Extra  |  Company News

May 23 Company Quick Takes: Chiesi gains Raxone rights; plus WuXi Vaccines, a Zika first and more

Chiesi gains rights to Santhera's Raxone for LHON
Santhera Pharmaceuticals Holding AG (SIX:SANN) granted Chiesi Farmaceutici S.p.A. (Parma, Italy) exclusive, worldwide rights outside of the U.S. and Canada to Raxone idebenone for Leber hereditary optic neuropathy and all other ophthalmological indications; the short-chain benzoquinone received EU approval for LHON in 2015. Santhera will receive CHF50 million ($49.5 million) up front and is eligible for sales milestones of up to CHF55 million ($54.4 million). Chiesi has an option to acquire full rights.

WuXi enters long-term vaccine manufacturing deal
WuXi Biologics Inc. (HKSE:2269) said its WuXi Vaccines JV will build an integrated vaccine manufacturing facility to supply an undisclosed company with commercial vaccine...

Read the full 521 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >